Search

Displaying results 8341 - 8350 of 8553 in total
  1. Drug

    EDP1815

    go.drugbank.com/drugs/DB16486
    Investigational

    EDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions such as gastrointestinal beha...

  2. Drug

    Tertatolol

    go.drugbank.com/drugs/DB13775
    Experimental

    Tertatolol is a beta blocker.

    Categories: Beta Blocking Agents, Non-Selective
  3. Drug

    Bisphenol A

    go.drugbank.com/drugs/DB06973
    Experimental

    Categories: Estrogens, Non-Steroidal
  4. Drug

    Pozanicline

    go.drugbank.com/drugs/DB05458
    Investigational

    ABT-089 is a neuronal nicotinic acetylcholine receptor agonist that may have therapeutic utility for the treatment of several neurological disorders including Alzheimer, Attention Deficit Hyperactivity

  5. Drug

    Diethanolamine

    go.drugbank.com/drugs/DB20489
    Investigational

    Diethanolamine has a monoisotopic molecular weight of 105.08 Da.

    Synonyms: N,n'-iminodiethanol
  6. Drug

    Xelaglifam

    go.drugbank.com/drugs/DB21598
    Investigational

    Xelaglifam has a monoisotopic molecular weight of 501.2 Da.

  7. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    Therefore, the broad inhibition of FGFR isoforms may be effective against different types of tumors. … [A257714] While effective, disease progression may occur 6 to 8 months after treatment with currently approved FGFR inhibitors is started, and this effect is usually associated with on-target resistance

  8. Drug

    Anpocogin

    go.drugbank.com/drugs/DB06552
    Investigational

    Recombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity.

  9. Drug

    Romlusevimab

    go.drugbank.com/drugs/DB16494
    Investigational

    Romlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.

  10. Drug

    GR270773

    go.drugbank.com/drugs/DB06427
    Investigational

    GR270773, was investigated in two clinical trials for its potential to treat sepsis: NCT00158769 (completed, comparing the effects of infusion between healthy adults and those with damaged livers) and NCT00089986 (completed with results,...